Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
“…16, 2014 ª2014 Elsevier Inc. stromal reaction in PDAC, a defining feature of this carcinoma, which accounts for the majority of the tumor tissue volume (Aguirre et al., 2003; Bardeesy et al., 2006a, 2006b; Gidekel Friedlander et al., 2009; Hingorani et al., 2003, 2005; Hruban et al., 2007; Ijichi…”
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
“…the LSL-KRASG12D mice Revised: November 26, 2003described here, it has recently been shown that pancreatic exPublished: December 10, 2003pression of oncogenic KRAS in the context of INK4a/ARF deficiency results in PDA with very short latency and high pene- References trance (Aguirre et al., 2003).”
BackgroundSelf-citationRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
“This contrasts with a previous report that Kras mutation and biallelic loss of p16/p19 promoted mPDA (Aguirre et al., 2003; Bardeesy et al., 2006) and may reflect differences in the genetic system or the initiating cellular compartment.”
ResultSelf-citationEMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
“Inflammation Promotes EMT, Invasiveness, and Dissemination The emergence of PanIN lesions is associated with the appearance of an inflammatory stroma characterized by activated fibroblasts andmyeloid-derived cells (Aguirre et al., 2003; Clark et al., 2007).”
BackgroundResultInfluentialOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
“Genetically engineered mouse models (GEMM) have provided evidence for oncogenic Kras (KrasG12D) as a major driver in PDAC initiation, with the aforementioned tumor suppressor genes constraining progression (Aguirre et al., 2003; Guerra et al., 2003; Hingorani et al., 2003).”
Self-citationKleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Self-citationGuidelines for the welfare and use of animals in cancer research
An ad hoc committee of the National Cancer Research Institute, Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,442
“…K-rasG12D+Ink4a/Arf deficiency or combined withTrp53R172H Metastatic lung cancer Metastatic pancreatic cancer (Johnson et al, 2001) (Aguirre et al, 2003; Hingorani et al, 2005) AML1/ETO or MLL fusion proteins AML AML (Zuber et al, 2009) MYCN Neuroblastoma, Rhabdomyosarcoma,…”
BackgroundThe Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Self-citationPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Guerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.012 · Cited by 1,224
“Most models involve expression of K-Ras oncogenes (Aguirre et al., 2003; Brembeck et al., 2003; Grippo et al., 2003; Hingorani et al., 2003; Quaife et al., 1987; Tuveson et al., 2006), although transgenic expression of other oncogenes such as polyoma middle T and growth-promoting molecules, including Shh, HB-EGF, and…”
BackgroundResultInfluentialHyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Self-citationMitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
“Tg (17, 18) and p48-CRE/LSL-KrasG12D/INK4a (18, 19) mice, respectively.”
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
“2005), Cdkn2a (Aguirre et al. 2003; Bardeesy et al. 2006), or Smad4 (Kojima et al.”
BackgroundInfluentialSingh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
“K-ras mutations occur most frequently in adenocarcinomas of the lung, pancreas, and colon, and mutational activation of K-Ras in these tissues is sufficient to initiate neoplasia in mice (Aguirre et al., 2003; Haigis et al., 2008; Johnson et al., 2001).”
BackgroundMethodInfluentialSelf-citationDominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
“(Trp53, Ink4A/Arf) in genetically engineered mice (GEM) recapitulates PanIN initiation and progression to pancreatic cancer (PC), similar to the clinical pathology (Aguirre et al., 2003; Guerra et al., 2007; Hingorani et al., 2003, 2005; Kelly et al., 2008).”
BackgroundYap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
“Immunohistochemical (IHC) analysis was performed as described earlier (Aguirre et al., 2003).”
Self-citationMaximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Self-citationRole of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Kopp, J. L., von Figura, G., Mayes, E., Liu, F.-F., Dubois, C. L., Morris, J. P., Pan, F. C., Akiyama, H., Wright, C. V. E., Jensen, K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.025 · Cited by 697
“Because previous studies have modeled PDA initiation mostly by expressing oncogenic Kras in all cell types of the pancreas (Aguirre et al., 2003; Hingorani et al., 2003, 2005), little is known about its cell of origin.”
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674
“…locus (encoding both p16INK4A and p19ARF), or of p53, does not induce pancreatic neoplasia; however, concurrent KrasG12D expression and inactivation of Ink4a/Arf or p53 drives the development of advanced PDAC with short latency (Aguirre et al. 2003; Hingorani et al. 2005; Bardeesy et al. 2006).”
BackgroundMethodInfluentialSelf-citationMutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Laklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G. E., Barrett, A. S., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 603
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mahadevan, D., & Von Hoff, D. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0686 · Cited by 601
“However, lung and liver metastases were rarely observed in these mice (33), indicating that directed activation of an oncogene and loss of a tumor suppressor in a genetic mouse model of PDA may not be a true reflection of human PDA, which may be due to species-specific gene expression and differential hard wiring of s…”
BackgroundTGF-β Tumor Suppression through a Lethal EMT
David, C. J., Huang, Y.-H., Chen, M., Su, J., Zou, Y., Bardeesy, N., Iacobuzio-Donahue, C. A., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.01.009 · Cited by 593
Self-citationBardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
Self-citationKRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2899 · Cited by 567
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
Self-citationGuerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516
“…of oncogenic insults including K-Ras oncogenes, loss of p16Ink4a/p19Arf or Trp53, and caerulein-induced pancreatitis often display invasive and metastatic properties, albeit those induced in adult animals require longer latencies (Aguirre et al., 2003; Hingorani et al., 2005; Guerra et al., 2007).”
BackgroundInfluentialGenetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
“This mutation is a key initiator, as evidenced by its presence in PanIN lesions (Kanda et al. 2012; Murphy et al. 2013) and the production of PanIN lesions in oncogenic Kras-drivenGEMMs (Hezel et al. 2006; Perez-Mancera et al. 2012a).”
InfluentialTGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523
Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502
“We used a previously described mouse model for PDA that carries coincident Kras and Ink4a/Arf mutations (32), as seen in >80% of human PDA, and integrated the Gli1-nLacZ knock-in reporter allele (33).”
BackgroundMethodSelf-citationAutophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations
Yang, A., Rajeshkumar, N. V., Wang, X., Yabuuchi, S., Alexander, B. M., Chu, G. C., Von Hoff, D. D., Maitra, A., & Kimmelman, A. C. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0362 · Cited by 486
“Sequence analysis of PDAC has shown that more than 90% of tumors possess KRAS mutations (10), and mouse models have validated the critical role of this oncogene in driving PDAC formation (11, 12) and in tumor maintenance (13).”
BackgroundDose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490
Khanna, C. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh261 · Cited by 463
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
“R40P murine pancreatic cancer cells derived from a spontaneous murine pancreatic tumor (13) were injected into the tail of the pancreas.”
BackgroundMethodGuillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421601112 · Cited by 454
“We used control mice (Ink4a/Arf fl/fl; LSL-KrasG12D) and mice bearing spontaneous PDAC (Pdx1-Cre; Ink4a/Arf fl/fl; LSL-KrasG12D) (14) with histological and clinical features similar to those reported in humans.”
BackgroundInfluentialEvolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Mueller, S., Engleitner, T., Maresch, R., Zukowska, M., Lange, S., Kaltenbacher, T., Konukiewitz, B., Öllinger, R., Zwiebel, M., Strong, A., et al. (2018) · Nature · doi:10.1038/nature25459 · Cited by 431
“For the generation of double-or triple-mutants, pancreas-specific Cre lines10,35,36 were intercrossed with Kras G12D-Panc (PK mice)9,10 only, or in addition with Cdkn2a Δ HOM-Panc (PKC mice)37, Trp53 Δ HOM-Panc (PKP mice)38,39 or Tgfbr2 Δ HET-Panc and Tgfbr2 Δ HOM-Panc (PKT mice)40 mice.”
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
“To deepen the analysis of hypoxic regions in PDAC, we used the Pancreatic and duodenal homeobox 1-recombinase (Pdx1-Cre);Lox Stop Lox (LSL)Kras;cyclin-dependent kinase inhibitor 2A(Ink4a/Arf) mouse models which develop PDAC with histological and clinical features commonly found in human PDAC (14).”
MethodHruban, R. H., Adsay, N. V., Albores-Saavedra, J., Anver, M. R., Biankin, A. V., Boivin, G. P., Furth, E. E., Furukawa, T., Klein, A., Klimstra, D. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2168 · Cited by 414
Self-citationOlivares, O., Mayers, J. R., Gouirand, V., Torrence, M. E., Gicquel, T., Borge, L., Lac, S., Roques, J., Lavaut, M.-N., Berthezène, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16031 · Cited by 413
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413
Self-citationHabbe, N., Shi, G., Meguid, R. A., Fendrich, V., Esni, F., Chen, H., Feldmann, G., Stoffers, D. A., Konieczny, S. F., Leach, S. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810097105 · Cited by 408
“In contrast, cooperating genetic lesions (mutant Ink4/Arf, p53, etc) dramatically alter the natural history of disease in compound transgenic animals, with accelerated and fully penetrant progression to invasive neoplasia (14, 15).”
BackgroundSenNet recommendations for detecting senescent cells in different tissues
Suryadevara, V., Hudgins, A. D., Rajesh, A., Pappalardo, A., Karpova, A., Dey, A. K., Hertzel, A., Agudelo, A., Rocha, A., Soygur, B., et al. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00738-8 · Cited by 408
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4 196 .”
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K. J., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 404
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391
“Postmortem analysis revealed multiple lesions including invasive and metastatic PDAC as well as anaplastic carcinomas that metastasized to multiple organs (Aguirre et al., 2003; Guerra et al., 2011).”
Roles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397
Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H.-J., Nwosu, Z. C., Halbrook, C. J., Menjivar, R. E., Kemp, S. B., Sirihorachai, V. R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0958 · Cited by 385
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia
De La O, J.-P., Emerson, L. L., Goodman, J. L., Froebe, S. C., Illum, B. E., Curtis, A. B., & Murtaugh, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810111105 · Cited by 397
“Like mPanINs described previously (2, 3), those found in both KrasG12D;Pdx1CreERT and KrasG12D;Rosa26NIC;Pdx1CreERT mice express the duct marker cytokeratin-19 (CK19) and produce periodic acid-Schiff (PAS)-reactive mucins (see supporting information (SI) Fig.”
BackgroundInfluentialNolan-Stevaux, O., Lau, J., Truitt, M. L., Chu, G. C., Hebrok, M., Fernández-Zapico, M. E., & Hanahan, D. (2009) · Genes & Development · doi:10.1101/gad.1753809 · Cited by 383
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Fujitani, Y., Fujitani, S., Wright, C. V. E., & Moses, H. L. (2006) · Genes & Development · doi:10.1101/gad.1475506 · Cited by 379
“The tumors in this study exhibited this tumorigenesis pathway as with the previous LSL-KrasG12D-based models (Aguirre et al. 2003; Hingorani et al. 2003, 2005).”
BackgroundMethodResultInfluentialIzeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.017 · Cited by 379
“, 2006) and biallelic p16/p19 deletion (Aguirre et al., 2003), albeit with distinct clinical and histopathologic features.”
BackgroundSelf-citationMutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer
Alam, A., Levanduski, E., Denz, P., Villavicencio, H. S., Bhatta, M., Alhorebi, L., Zhang, Y., Gomez, E. C., Morreale, B., Senchanthisai, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.003 · Cited by 372
Self-citationWang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
“Accordingly, mim- icking loss of heterozygosity of Cdkn2a by inactivation of one allele using floxed Cdkn2a mice (Bardeesy et al., 2006) accelerated PDAC formation in the PIK3CAH1047R and KrasG12D model (Figures S2G and S2H).”
InfluentialUroplakins in urothelial biology, function, and disease
Wu, X.-R., Kong, X.-P., Pellicer, A., Kreibich, G., & Sun, T.-T. (2009) · Kidney International · doi:10.1038/ki.2009.73 · Cited by 354
Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras
Friedlander, S. Y. G., Chu, G. C., Snyder, E. L., Girnius, N., Dibelius, G., Crowley, D., Vasile, E., DePinho, R. A., & Jacks, T. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.027 · Cited by 338
“Temporally Restricted Activation of Oncogenic K-Ras in Distinct Cell Populations of the Adult Pancreas Activation of oncogenic K-Ras in the common pancreatic embryonic progenitor in the Pdx1Cre;LSL-Kras model results in mPanIN formation and spontaneous progression to PDAC (Aguirre et al., 2003; Hingorani et al., 2003).”
BackgroundMethodInfluentialSelf-citationMicroenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism
Biancur, D. E., Paulo, J. A., Małachowska, B., Quiles Del Rey, M., Sousa, C. M., Wang, X., Sohn, A. S. W., Chu, G. C., Gygi, S. P., Harper, J. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15965 · Cited by 315
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
Provenzano, P. P., & Hingorani, S. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.569 · Cited by 323
“…(2013) 108, 1–8 | doi: 10.1038/bjc.2012.569 www.bjcancer.com | DOI:10.1038/bjc.2012.569 1 which they arise, drive, and shape disease progression (Aguirre et al, 2003; Hingorani et al, 2003, 2005; Izeradjene et al, 2007), although efforts to target them directly to treat pancreas cancer have…”
BackgroundInfluentialmiRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Yu, S., Lu, Z., Liu, C., Meng, Y., Ma, Y., Zhao, W., Liu, J., Yu, J., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4531 · Cited by 328
“Overexpression of miR-96 dampens the Akt signaling pathway Activation of the KRAS pathway has been well documented in various tumor types, such as lung cancer (23, 24), breast cancer (25), colon cancer (26), and pancreatic cancer (27).”
BackgroundA Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B., Dankort, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320
Stromal biology of pancreatic cancer
Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 317
“Finally, comparative array-CGH analysis of human PDAC has allowed us to identify a wealth of candidate genes involved in PDAC formation [Aguirre et al., 2003].”
BackgroundInfluentialSelf-citationHedgehog/Ras interactions regulate early stages of pancreatic cancer
Pasca di Magliano, M., Sekine, S., Ermilov, A., Ferris, J., Dlugosz, A. A., & Hebrok, M. (2006) · Genes & Development · doi:10.1101/gad.1470806 · Cited by 307
“The significance of increased Kras signaling in pancreatic cancer is supported by the observation that conditional expression of Kras, the most common mutation in human tumors, results in formation of PanIN lesions and pancreatic tumors in transgenic PdxCre;Kras mice (Aguirre et al. 2003; Hingorani et al. 2003, 2005).”
BackgroundKeller, C., Arenkiel, B. R., Coffin, C. M., El-Bardeesy, N., DePinho, R. A., & Capecchi, M. R. (2004) · Genes & Development · doi:10.1101/gad.1244004 · Cited by 304
“Because the INK4a/ARF gene products influence both Trp53 and pRb pathways, we sought to determine which pathway was primarily responsible for rhabdomyosarcomagenesis.”
MethodInfluentialSelf-citationHosein, A. N., Huang, H., Wang, Z., Parmar, K., Du, W., Huang, J., Maitra, A., Olson, E., Verma, U., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.129212 · Cited by 302
Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells
Ji, Z., Mei, F. C., Xie, J., & Cheng, X. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611089200 · Cited by 296
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas
Stanger, B. Z., Stiles, B., Lauwers, G. Y., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K.-H., McLaughlin, M., Brown, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.015 · Cited by 294
“In particular, other Ras signals may protect acinar cells from the apoptosis that occurs in Pdx1-Cre;Ptenlox/lox mice, accounting for the greater ductal specificity of the Pdx1-Cre;LSL-KrasG12D phenotype (Aguirre et al., 2003).”
BackgroundInfluentialSelf-citationPancreatic Cancer: Basic and Clinical Aspects
Schneider, G., Siveke, J. T., Eckel, F., & Schmid, R. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.001 · Cited by 289
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
“In addition, the development of highly invasive and metastatic pancreatic adenocarcinoma in mice is supported by the cooperativity of oncogenic K-Ras and deficiency of Ink4A/Arf, a G1 cyclin-dependent kinase inhibitor (Aguirre et al., 2003).”
BackgroundSeeley, E. S., Carrière, C., Goetze, T., Longnecker, D. S., & Korc, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1290 · Cited by 283
“pancreatic cancer cell line was generated as described (30).”
BackgroundMethodYachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1215 · Cited by 280
“Furthermore, although genetically engineeredmousemodels indicate that the concomitant expression of thesemutated genes is crucial to progress to invasion and metastasis in PDACs (15–19), the extent to which the coexistence of 3 or more of these altered genes in the same PDAC influence thebiologic behavior and survival…”
BackgroundInfluentialEGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer
Shankar, S. (2008) · Frontiers in Bioscience · doi:10.2741/2691 · Cited by 273
Molecular genetics of pancreatic intraepithelial neoplasia
Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A. (2007) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-006-1166-5 · Cited by 269
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273
Pancreatic cancer–associated stroma production
Korc, M. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.05.004 · Cited by 268
“Mice carrying an activate K-ras allele and harboring either a partially inactivated p53 gene or a deletion in the Ink4a locus exhibit accelerated tumor progression and develop distant metastases [15,16], underscoring the importance of multiple hits in the progression of PanINs to PDAC.”
BackgroundChiou, S.-H., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Grüner, B. M., Chuang, C.-H., et al. (2015) · Genes & Development · doi:10.1101/gad.264861.115 · Cited by 264
“…engineered PDAC models were developed, few technical advances have been made, and generating the mice required to investigate a gene of interest in the established PDAC models remains a time-consuming and costly endeavor (Aguirre et al. 2003; Hingorani et al. 2003, 2005; Saborowski et al. 2014).”
BackgroundIjichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256
“Importantly, inactivation of tumor suppressor genes p16INK4a (8), p53 (9, 10), or Tgfbr2 (TGF-β receptor type II) (11) dramatically accelerated PDAC progression in the context of Kras activation.”
BackgroundA Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development
Faca, V. M., Song, K. S., Wang, H., Zhang, Q., Krasnoselsky, A. L., Newcomb, L. F., Plentz, R. R., Gurumurthy, S., Redston, M. S., Pitteri, S. J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050123 · Cited by 257
“Mice harboring Pdx1-Cre Kras Ink4a/Arf lox/lox mutations exhibit stereotypical neoplastic progression from pancreatic cancer precursor lesions (PanINs) present at ;2 wk of age to advanced PDAC by 6 to 10 wk of age [13].”
BackgroundMethodInfluentialSelf-citationThe KRAS oncogene: Past, present, and future
Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.10.001 · Cited by 252
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
Self-citationCombining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes
Ko, J., Bhagwat, N., Yee, S. S., Ortiz, N., Sahmoud, A., Black, T., Aiello, N. M., McKenzie, L., O’Hara, M., Redlinger, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b05503 · Cited by 249
Update on pancreatic intraepithelial neoplasia.
Hruban, R. H., Maitra, A., & Goggins, M. (2008) · PubMed Central · Cited by 347
Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma
Kelly, K. A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., DePinho, R. A., Mahmood, U., & Weissleder, R. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050085 · Cited by 240
“Breeding, genotyping, and analysis were performed as previously published [11,12].”
BackgroundMethodSelf-citation
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.